TetraLogic Pharmaceuticals Appoints Dr. Andrew Pecora to Its Board of Directors.
John M. Gill, President and Chief Executive Officer of TetraLogic Pharmaceuticals, stated, "We are delighted to welcome Dr. Pecora to our Board. He brings to our organization a wealth of expertise in the field of hematology-oncology and cancer research, including clinical trial design, and is a pioneer in the use of Granulocyte Cell Stimulating Factor (GCSF) for the supportive care of cancer patients. Additionally, under his leadership, the Hackensack University Cancer Center, where he is presently Chairman and Executive Administrative Director, has become one of the top cancer centers in the United States. As Founder of two life sciences companies, Dr. Pecora also brings welcome experience in business development. We look forward to numerous contributions by Dr. Pecora as TetraLogic Pharmaceuticals moves from the pre-clinical to clinical stages of product development, and beyond."
Dr. Pecora is currently in private practice in Hackensack, NJ. In addition, he has spent the last 18 years in various capacities at Hackensack University Medical Center in Hackensack, NJ, currently serving as Chairman and Executive Administrative Director of The Cancer Center, Senior Scientist at the Institute for Biomedical Research, and Attending Physician of Internal Medicine, Member, Section of Hematology-Oncology. During his tenure at Hackensack University Medical Center, Dr. Pecora has also held the roles of Chairman and Director of The Cancer Center; Director, Hematology and Medical Oncology; Chief, Adult Blood and Marrow Stem Cell Transplant Service; and Medical Director, Stem Cell Collection and Storage Service, among others.
Among his numerous other professional positions, Dr. Pecora is co-Founder and co-managing partner of Northern New Jersey Cancer Associates. He is also founder and Chairman of Amorcyte, Inc., a privately funded biotechnology company developing cell therapy products to treat cardiovascular disease, and Co-founder, Chairman and Chief Executive Officer of Progenitor Cell Therapy, LLC, a client-based cell therapy services company supporting the development and commercialization of cellular therapies. Dr. Pecora also currently serves as Editor of the American Society of Blood and Marrow Transplantation e-News; a Member of the Medical Advisory Board of The Bone Marrow Foundation; and Member, New Jersey Working Group to Improve Outcomes in Cancer Patients.
Dr. Pecora has authored or co-authored numerous articles, abstracts, books, chapters and monographs and is a frequent lecturer in the field of cancer. He received his Bachelor of Science degree in Biology from Seton Hall University and his Medical Degree from the University of Medicine and Dentistry of New Jersey. He completed both his postdoctoral internship in internal medicine as well as his residency in the Department of Internal Medicine at The New York Hospital, located in New York, NY, and completed a fellowship in hematology-oncology at Memorial Sloan-Kettering Cancer Center, also in New York. He is licensed to practice in both New Jersey and New York.
About TetraLogic Pharmaceuticals
TetraLogic Pharmaceuticals is a privately held company focused on discovering and developing new oncology drugs. Its lead program, IAP antagonists, are in preclinical development and are slated to enter clinical trials during the second half of 2007. Other apoptosis related drug discovery programs are at an earlier stage of development. To date, TetraLogic has raised a total of $44 million through private financings. The Company's investors include Amgen Ventures, HealthCare Ventures, Kammerer Associates, Latterell Venture Partners, PA Early Stage Partners, Quaker BioVentures and the Vertical Group. For additional information, please refer to the Company's website at www.tetralogicpharma.com.
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 30, 2007|
|Previous Article:||Intelliden Awarded Patents for Configuration of Network Devices.|
|Next Article:||ink2 Debuts the Web's First Personalized Print-on-Demand Platform at DEMO 07.|